Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prostate medication, metabolism and gut microbiota (PROMED)
2022-500618-24-00Phase 4Authorised
- Sponsor
- Turku University Hospital
- Start
- Aug 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of degarelix, alpha blocker + 5-alpha reductase inhibitor, dutasteride, finasteride and tamsulosin in prostate cancer (PCa) and benign prostatic hyperplasia (BPH) (4 arms), sponsored by Turku University Hospital. Planned start Aug 2022; status: authorised.
02
Drugs
degarelixalpha blocker + 5-alpha reductase inhibitordutasteridefinasteridetamsulosin
03
Conditions
prostate cancer (PCa)benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2022-500618-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500618-24-00.